Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Cardiac Glycosides in Heart Failure with Reduced Ejection Fraction in the Era of Contemporary Guideline-Directed Medical Therapy: A Systematic Review and Meta-Analysis
Session:
Sessão de Posters 11 - Dos digitálicos aos diuréticos no espectro da insuficiência cardíaca
Speaker:
Luísa Pinheiro
Congress:
CPC 2026
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.4 Chronic Heart Failure – Treatment
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Luísa Pinheiro; Emídio Mata; Bernardo Resende; Ana Marta Pinto; Bárbara Lage Garcia; João Português; Sílvia Ribeiro; Olga Azevedo; António Lourenço
Abstract
<p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:12pt"><strong>Introduction:</strong> Heart failure (HF) with reduced ejection fraction (HFrEF) remains a major challenge despite widespread use of the four pillars of contemporary guideline-directed medical therapy (GDMT). Cardiac glycosides, historically used for their inotropic and neurohormonal effects, have largely fallen out of favor with the DIG trial (1997), showing reduction of HF hospitalizations but no mortality benefit. However, that trial predated modern GDMT and device therapy. Recent data, including the DIGIT-HF trial (2023), have renewed interest in this drug class by suggesting a potential benefit of digitoxin in optimally treated patients.</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:12pt"><strong>Aim:</strong> Evaluate the impact of cardiac glycosides on patients with HFrEF receiving contemporary background therapy.</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:12pt"><strong>Methods:</strong> Four databases were searched for randomized trials (RCT) or propensity-matched studies recruiting adults with HFrEF (LVEF<50%) after 2000, comparing cardiac glycosides with standard care and reporting at least one primary outcome (all-cause mortality or heart-failure hospitalization). Data were pooled using an inverse-variance random-effects model.</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:12pt"><strong>Results</strong>: Six studies met inclusion criteria, one RCT (DIGIT-HF) and five propensity-matched observational cohorts (2000–2023), encompassing ~10000 patients (4500 cardiac glycoside users, 5500 controls). DIGIT-HF assessed digitoxin; the remaining studies evaluated digoxin. Pooled analysis demonstrated no significant difference in all-cause mortality (HR 1.01 [0.67–1.53] I²=77%) with cardiac glycosides significantly reducing HF hospitalizations (HR 0.84 [0.76–0.93] I²=0%). No significant effect was observed for all-cause hospitalizations (HR 0.95 [0.83–1.10] I²=53%). Cardiovascular mortality, reported only in DIGIT-HF, was similar between groups (HR 0.87 [0.67–1.11]).</span></span></p> <p style="text-align:justify"><span style="font-family:Arial,Helvetica,sans-serif"><span style="font-size:12pt"><strong>Discussion:</strong> This post-2000 era meta-analysis suggests that cardiac glycosides may still provide benefit by reducing HF hospitalizations among patients with HFrEF receiving contemporary GDMT. The interpretation of mortality outcomes is, however, limited by the high heterogeneity observed across studies. Digoxin dosing differences, potential residual bias despite propensity matching, and differences in pharmacokinetics between digoxin and digitoxin, together with wide variation in recruitment periods, may have influenced the results and contributed to heterogeneity. These findings highlight the crucial need for RCTs to clarify the role of cardiac glycosides as adjunctive therapy in contemporary HFrEF.</span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site